Evidence map›Paper›PMID 35821477›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Generation, Characterization, and Applications of Influenza A Reporter Viruses.

Kevin Chiem, Aitor Nogales, Luis Martinez-Sobrido

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
15.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Bacterial Artificial Chromosome Reverse Genetics Approaches for SARS-CoV-2.Methods in molecular biology (Clifton, N.J.) · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kevin ChiemTexas Biomedical Research Institute, San Antonio, TX, USA.
Aitor NogalesCenter for Animal Health Research, INIA-CISA/CSIC, Madrid, Spain. nogales.aitor@inia.es.
Luis Martinez-SobridoTexas Biomedical Research Institute, San Antonio, TX, USA. lmartinez@txbiomed.org.
Texas Biomedical Research Institute · US

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Effect of Neonatal Hyperoxia on Alveolar Development and InfectionR01HL091968 · NHLBI · UNIVERSITY OF ROCHESTER · PI O'REILLY, MICHAEL A · 2009 to 2021
$5.4M
Development of a High-Throughput Microfluidics-Enabled Functional Assay for Rapidly Identifying Neutralizing AntibodiesR01AI141607 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI DE FIGUEIREDO, PAUL, HAN, ARUM · 2019 to 2023
$3.4M
Dynamics of the protective vaccine-induced human influenza neuraminidase B cell responseR01AI145332 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2019 to 2022
$3.0M
The origin and future protective activity of SARS-CoV-2 RBD specific neutralizing antibodiesR01AI161175 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KOBIE, JAMES J, MARTINEZ-SOBRIDO, LUIS · 2021 to 2024
$2.5M
NHLBI NIH HHS R01 HL091968NIAID NIH HHS 75N93021C00014NIAID NIH HHS R01 AI141607NIAID NIH HHS R01 AI145332NIAID NIH HHS R01 AI161175
6 · The paper itself

Abstract

Secondary experimental procedures such as immunostaining have been utilized to study wild-type influenza A viruses (IAV) but are inadequate to rapidly determine the virus in infected cells or for the high-throughput screening (HTS) of antivirals or neutralizing antibodies. Reverse genetics approaches have allowed the generation of recombinant IAV expressing bioluminescent (BL) reporters or fluorescent proteins (FPs). These approaches can easily track viral infections in cultured cells and in validated animal models of infection using in vivo imaging systems (IVIS). Here, we describe the experimental procedures to generate recombinant monomeric (m)Cherry-expressing influenza A/Puerto Rico/8/34 (PR8-mCherry) H1N1 by altering the non-structural (NS) vRNA segment and its use in mCherry-based microneutralization assays to assess antivirals and neutralizing antibodies. The experimental procedures could be used for the generation of other recombinant influenza virus types (e.g., influenza B) or IAV subtypes (e.g., H3N2) expressing mCherry or other BL reporters or FPs from the NS or other vRNA segment. These recombinant reporter-expressing viruses represent an excellent toolbox for the identification of prophylactics or therapeutics for the treatment of influenza viral infections in HTS settings as well as to study different aspects related with the biology of influenza viruses and/or its interaction with the host.

Indexed as

Influenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza, HumanAnimalsAntibodies, NeutralizingAntiviral AgentsHumansInfluenza A Virus, H3N2 SubtypeLuminescent ProteinsVirus ReplicationAntibodies, NeutralizingAntiviral AgentsLuminescent ProteinsInfluenza A virusmCherryMicroneutralization assayRecombinant virusesReporter genesReporter virusesReverse genetics

Identifiers

PMID35821477
PMCPMC10285581
OpenAlexW4285132509

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.